10-K: Atossa Therapeutics Advances Endoxifen, Faces Losses

Atossa Therapeutics reports progress in its (Z)-endoxifen clinical trials for breast cancer and rare diseases, alongside continued operating losses and a recent reverse stock split.

Summary

• Atossa Therapeutics is a clinical-stage biopharmaceutical company focused on developing innovative medicines for oncology, particularly breast cancer, and certain rare diseases.
• The lead drug candidate, oral (Z)-endoxifen, is a selective estrogen receptor modulator/degrader (SERM/D) currently in Phase 2 clinical development.
• (Z)-endoxifen is the most active metabolite of Tamoxifen, offering greater potency and activity independent of patient-specific metabolic variability.
• The Karisma-(Z)-endoxifen Phase 2 study for mammographic breast density (MBD) concluded in June 2024, with initial data showing significant MBD reductions of 17.3% (1mg dose) and 23.5% (2mg dose) compared to placebo (0.27% change). Top-line data is expected in the first half of 2026.
• In the I-SPY 2 Endocrine Optimization Pilot (EOP) Phase 2 study for ER+/HER2early breast cancer, the 10mg dose of (Z)-endoxifen demonstrated excellent tolerability (95% patient completion), reduced Ki-67 proliferation index, and a median MRI functional tumor volume reduction of approximately 72%.
• The I-SPY 2 EOP study is expanding to a 40mg daily dose, including combination therapies with abemaciclib and elagolix, with data expected in the second half of 2026.
• The RECAST DCIS study is investigating (Z)-endoxifen as a neoadjuvant treatment for ductal carcinoma in situ (DCIS) to potentially reduce the need for surgery, with enrollment ongoing and early findings suggesting feasibility.
• The EVANGELINE Phase 2 study for premenopausal women with ER+/HER2breast cancer showed 86% of patients achieved a Ki-67 value of 10% or less at Week 4 with 40mg (Z)-endoxifen plus ovarian function suppression (OFS). Enrollment is expected to be complete in the second quarter of 2026.
• (Z)-endoxifen is also being explored for rare diseases, including Duchenne Muscular Dystrophy (DMD), women carriers of DMD, and McCune-Albright Syndrome (MAS).
• The company received FDA Rare Pediatric Disease Designation and Orphan Drug Designation for (Z)-endoxifen for the treatment of DMD in December 2025 and early 2026, respectively.
• Atossa Therapeutics reported a net loss of $34.8 million for the year ended December 31, 2025, an increase from $25.5 million in 2024, and an accumulated deficit of $246.6 million.
• Cash and cash equivalents decreased to $41.3 million as of December 31, 2025, from $71.1 million in 2024.
• The company's ability to continue as a going concern is dependent on obtaining adequate additional capital.
• A 1-for-15 reverse stock split was effected on February 2, 2026, to regain compliance with Nasdaq's minimum bid price requirement, which was achieved by February 17, 2026.
• An At the Market Offering Agreement was entered into on February 20, 2026, to sell up to $50 million of common stock.
• The company is contesting two petitions filed by Intas Pharmaceuticals Ltd. on April 3, 2025, seeking to invalidate U.S. Patents No. 12,071,391 and No. 11,261,151 related to (Z)-endoxifen.

Sentiment

Score: 4

Explanation: StockSavvy.ai views this as a mixed filing. While clinical progress for (Z)-endoxifen in breast cancer and rare diseases is positive, the significant increase in net losses, declining cash reserves, and explicit 'going concern' warning indicate substantial financial challenges and a high need for capital.

Positives

• (Z)-endoxifen demonstrated early signs of anti-tumor activity in an ongoing neoadjuvant clinical study, including one complete response, multiple partial responses, substantial reductions in Ki-67 proliferation, and tumor shrinkage by MRI.
• The Karisma-(Z)-endoxifen study showed significant mammographic breast density (MBD) reductions of 17.3% (1mg dose) and 23.5% (2mg dose) compared to placebo, with the 1mg dose generally well tolerated.
• The I-SPY 2 Endocrine Optimization Pilot study reported excellent tolerability for the 10mg dose of (Z)-endoxifen, with approximately 95% of patients completing at least 75% of planned therapy and predominantly low-grade adverse events.
• Biologic activity in I-SPY 2 EOP included reductions in Ki-67 proliferation index, a median MRI functional tumor volume reduction of approximately 72%, and clearance of circulating tumor DNA (ctDNA) in a majority of patients.
• The company received FDA Rare Pediatric Disease Designation and Orphan Drug Designation for (Z)-endoxifen for the treatment of Duchenne Muscular Dystrophy (DMD), which may provide incentives like a potential Priority Review Voucher (PRV) and market exclusivity.
• A proprietary manufacturing process for (Z)-endoxifen has been developed, ensuring multiple dosage strengths and manufacturing redundancies.
• The company maintains a strong intellectual property portfolio with 24 issued patents and 141 pending applications, with patent protection for (Z)-endoxifen expected through at least November 17, 2038.
• Nasdaq compliance was regained on February 17, 2026, following a 1-for-15 reverse stock split, ensuring continued listing on The Nasdaq Capital Market.

Negatives

• The company reported a net loss of $34.8 million for the year ended December 31, 2025, an increase from $25.5 million in 2024, contributing to an accumulated deficit of $246.6 million.
• Cash and cash equivalents significantly decreased from $71.1 million at December 31, 2024, to $41.3 million at December 31, 2025.
• Operating expenses increased by $9.5 million, from $27.6 million in 2024 to $37.1 million in 2025, driven by higher research and development and general and administrative costs.
• The company explicitly states that 'substantial doubt exists about our ability to continue as a going concern' due to a lack of ongoing revenue to cover operating costs.
• Interest income decreased by $1.7 million in 2025 compared to 2024, primarily due to a decrease in average funds invested.
• An impairment charge of $1.7 million was recorded in 2024 due to the impairment of an investment in Dynamic Cell Therapies, Inc., which ceased operations.
• The 2mg dose group in the Karisma-(Z)-endoxifen study experienced higher rates of certain adverse events, including hot flashes, night sweats, and vaginal discharge.
• Intas Pharmaceuticals Ltd. filed two petitions on April 3, 2025, seeking to invalidate key patents (U.S. Patent No. 12,071,391 and No. 11,261,151) related to (Z)-endoxifen, and a prior patent (U.S. Patent No. 11,572,334) was found unpatentable on January 29, 2025.
• A liability of $1.1 million was recorded as of December 31, 2025, for the Australian R&D tax rebate due to uncertainty regarding the full tax position being sustained under audit.
• The company's former executive, Heather Rees, terminated employment effective November 15, 2025, as detailed in a separation agreement.

Risks

• We have a history of operating losses and expect to continue to incur losses in the future.
• We have not established sources of ongoing revenue to cover operating costs and allow us to continue as a going concern.
• We will need to raise substantial additional capital in the future to fund our operations and we may be unable to raise such funds when needed and on acceptable terms.
• We may expend our capital resources in ways that you do not agree or that do not produce stockholder value.
• Any products we may develop may never achieve significant commercial market acceptance.
• We may be unable to establish sales, marketing and commercial supply capabilities.
• The loss of the services of our Chief Executive Officer could adversely affect our business.
• Our acquisitions of, collaborations with, licenses with and investments in, other businesses may not yield expected benefits.
• We may experience difficulty in locating, attracting and retaining experienced and qualified personnel.
• Compounds and methods that appear promising in research and development may fail to reach later stages of development.
• Clinical trials may take longer to complete than expected or may not be completed at all, and interim, top-line or preliminary clinical trial data reports may ultimately differ from actual results.
• We may not obtain or maintain the regulatory approvals required to develop or commercialize some or all of our products.
• Rare pediatric disease designation for any of our product candidates does not guarantee that the NDA for the product will qualify for a priority review voucher upon approval, and it does not lead to a faster development or regulatory review process, or increase the likelihood that our product candidates will receive marketing approval.
• We may not enjoy the market exclusivity benefits of our orphan drug designations.
• We are developing our products for patients who are severely ill, and patient deaths that occur in our clinical trials could negatively impact our business even if such deaths are not shown to be related to our drugs.
• We are dependent on third-party service providers for a number of critical operational activities as well as for clinical trial activities.
• We may encounter delays in our clinical trials or may not be able to conduct our trials in a timely manner.
• Our clinical trials may fail to demonstrate adequately the efficacy and safety of our product candidates.
• Our products and services may expose us to possible litigation and product liability claims.
• The deployment of artificial intelligence (AI) in our or our collaborators' product candidates could adversely affect our business, reputation or financial results.
• Business disruptions, including natural disasters, severe weather, and pandemics, could seriously harm our future revenue and financial condition and increase our costs and expenses.
• We maintain our cash at financial institutions, often in balances that exceed federally-insured limits.
• Our ability to use net operating loss carryforwards and research tax credits to reduce future tax payments may be limited or restricted.
• We, or our wholly-owned subsidiary, could lose our ability to operate in Australia, or our subsidiary may be unable to benefit from the past or future R&D tax rebates available under current Australian regulations.
• We may not be able to protect our proprietary technology.
• Obtaining and maintaining our patent protection depends on compliance with various procedural, document submission, fee payment and other requirements imposed by governmental patent agencies.
• Changes in U.S. patent law could diminish the value of patents in general.
• We may not be able to protect our intellectual property rights throughout the world.
• Our current patent portfolio may not include all patent rights needed for the full development and commercialization of our products. We cannot be sure that patent rights we may need in the future will be available for license on commercially reasonable terms, or at all.
• Third-party claims alleging intellectual property infringement may prevent or delay our drug discovery and development efforts.
• We cannot assure you that our current or future products will not infringe on existing or future patents.
• We may be subject to claims that our employees, consultants or independent contractors have wrongfully used or disclosed confidential information of third parties.
• We may be unable to adequately prevent disclosure of trade secrets and other proprietary information.
• Legislative or regulatory reforms may make it more difficult and costly for us to obtain regulatory approval of our product candidates and to manufacture, market and distribute our products after approval is obtained.
• Disruptions at the FDA and other government agencies could negatively affect the review of our regulatory submissions.
• Our inadvertent or unintentional failure to comply with the complex government regulations concerning patients' privacy, data subjects, and of medical records could subject us to fines and adversely affect our reputation.
• Significant disruptions in our information technology systems or breaches of data security could adversely affect our business.
• The failure to comply with complex federal and state laws and regulations related to submission of claims for services could result in significant monetary damages and penalties and exclusion from the Medicare and Medicaid programs.
• We face significant competition from other biotechnology and pharmaceutical companies.
• Our employees and third-party partners may engage in misconduct or other improper activities.
• Our business involves risk associated with handling hazardous and other dangerous materials.
• Our shares of common stock are listed on the Nasdaq Capital Market, but we cannot guarantee that we will be able to maintain compliance with the continued listing standards or satisfy the continued listing standards going forward.
• The sale of a substantial number of shares of our common stock into the market may cause substantial dilution.
• The trading price of our common stock has been and is likely to continue to be volatile.
• We have never paid dividends and we do not anticipate paying dividends in the future.
• The ownership of our common stock may become concentrated among a small number of stockholders.
• We may be unable to implement and maintain effective internal control over financial reporting.
• The requirements of being a public company may strain our resources, result in litigation, and divert management's attention.
• The anti-takeover provisions in our governing documents and Delaware law could delay or prevent a change in control which could reduce the market price of our common stock.
• The exclusive forum provision in our Amended and Restated Certificate of Incorporation could limit our stockholders' ability to obtain a favorable judicial forum for disputes.
• If securities or industry analysts do not publish research or publish inaccurate or unfavorable research about our business, the price of our common stock and trading volume could decline.

Future Outlook

The company expects to incur ongoing operating losses for the foreseeable future as it continues to develop its therapeutic programs. Existing resources are anticipated to fund planned operations for the next 12 months, but additional capital will be needed longer-term. Top-line data from the Karisma-(Z)-endoxifen study is expected in the first half of 2026, and data from the I-SPY 2 EOP combination therapy arms is expected in the second half of 2026. The company intends to pursue additional Orphan Drug and Rare Pediatric Disease designations for women carriers of DMD and McCune-Albright Syndrome in the first half of 2026. Final decisions on patent challenges are expected by November 3, 2026.

Management Comments

• "We believe these designations provide us with several potential strategic benefits, including incentives, such as a potential Priority Review Voucher (PRV) for future FDA applications, other regulatory support, and potential market exclusivity for a period of time." (Regarding DMD designations)
• "We believe similar efficacy could potentially apply to women carriers of DMD."
• "For MAS, we believe (Z)-endoxifen could potentially be an effective hormone blocker, significantly reducing the effects of early onset puberty in young girls."
• "We expect our existing resources will be sufficient to fund our planned operations for the next 12 months; additional capital resources will be needed to fund operations longer-term."
• "The Company intends to continue to vigorously contest the 391 PGR Petition and the 151 IPR Petition and believes that the Patents were properly granted and include valid and enforceable claims and that the risk of experiencing financial loss related to the Petitions is remote."

Industry Context

StockSavvy.ai notes that Atossa Therapeutics operates in the highly competitive biopharmaceutical sector, focusing on oncology and rare diseases, particularly breast cancer and Duchenne Muscular Dystrophy. The global ER+ breast cancer treatment market is projected to reach $30 billion by 2030, and the DMD market is expected to grow to $10 billion by 2030, indicating significant market opportunities for successful drug candidates. The company's strategy to develop a differentiated SERM/D like (Z)-endoxifen, which bypasses CYP2D6 metabolism, addresses a key challenge with existing Tamoxifen therapies. Its pursuit of rare disease indications with Orphan Drug and Rare Pediatric Disease designations aligns with industry trends leveraging regulatory incentives like Priority Review Vouchers. The increasing use of AI in drug discovery by competitors highlights the need for continuous innovation and investment in advanced technologies.

Comparison to Industry Standards

• The reported MBD reduction of 17.3% (1mg) and 23.5% (2mg) for (Z)-endoxifen in the Karisma study appears promising, as there are currently no FDA-approved treatments specifically for MBD reduction. This positions (Z)-endoxifen uniquely if approved.
• The 72% median MRI functional tumor volume reduction and Ki-67 suppression in the I-SPY 2 EOP study for ER+/HER2breast cancer are strong early indicators of anti-tumor activity, especially given that endocrine therapies are typically cytostatic rather than tumor-shrinking. This compares favorably to standard endocrine therapies which primarily aim to halt growth.
• The tolerability profile of (Z)-endoxifen, with 95% patient completion in I-SPY 2 EOP and predominantly low-grade adverse events, suggests a potentially better patient experience compared to some existing breast cancer treatments that can have more severe side effects.
• The receipt of FDA Rare Pediatric Disease and Orphan Drug Designations for DMD positions (Z)-endoxifen to potentially benefit from accelerated review and market exclusivity, similar to other rare disease therapies that have leveraged these incentives (e.g., Sarepta Therapeutics' therapies for DMD).
• The company's accumulated deficit of $246.6 million and continued operating losses are typical for clinical-stage biopharmaceutical companies, which require substantial R&D investment before potential revenue generation. This is comparable to many early-stage biotech firms that operate at a loss for extended periods.

Management Changes

Corporate Governance

Legal Proceedings

• Intas Pharmaceuticals Ltd. filed a Petition for Post Grant Review (PGR) on April 3, 2025, seeking to invalidate U.S. Patent No. 12,071,391 ('Methods for Making and Using Endoxifen') on alleged grounds of anticipation, obviousness, lack of written description, and lack of enablement.
• Intas Pharmaceuticals Ltd. also filed a Petition for Inter Partes Review (IPR) on April 3, 2025, seeking to invalidate U.S. Patent No. 11,261,151 ('Methods for Making and Using Endoxifen') on alleged grounds of anticipation and obviousness.
• The Patent Trial and Appeal Board (PTAB) granted institution of both the PGR and IPR petitions on November 3, 2025.
• The company submitted responses to both the 391 PGR Petition and the 151 IPR Petition on January 26, 2026.
• Final written decisions for both proceedings are expected by November 3, 2026.
• On January 29, 2025, the PTAB issued a final written decision finding all claims of U.S. Patent No. 11,572,334 unpatentable, which was related to a prior petition by Intas Pharmaceuticals Ltd.

Stakeholder Impact

• Shareholders face potential significant dilution from future equity raises, continued stock price volatility, and the risk of investment loss due to the company's 'going concern' issues. The reverse stock split aimed to maintain Nasdaq listing, which is generally beneficial for market access.
• Employees saw an increase in R&D compensation due to headcount growth, and stock-based compensation plans are in place for attraction and retention. The departure of an executive indicates some management transition.
• Patients could benefit from new therapeutic options in breast cancer and rare diseases if (Z)-endoxifen development is successful. However, clinical trial delays or failures would negatively impact the availability of these potential treatments.
• Creditors face increased risk due to the company's 'going concern' warning and ongoing operating losses.

Next Steps

• Report top-line data from the Karisma-(Z)-endoxifen study in the first half of 2026.
• Begin receiving data from the I-SPY 2 EOP combination therapy arms in the second half of 2026.
• Complete enrollment in the EVANGELINE study in the second quarter of 2026.
• Continue work on hypotheses and potential clinical trial protocols for women carriers of DMD in 2026.
• Pursue Orphan Drug Designation for women carriers of DMD in the first half of 2026.
• Seek Rare Pediatric Disease and Orphan Drug designations for McCune-Albright Syndrome (MAS) in the first half of 2026.
• Final written decisions for the 391 PGR and 151 IPR patent proceedings are expected by November 3, 2026.
• File the Definitive Proxy Statement for the 2026 Annual Meeting of Stockholders within 120 days after December 31, 2025.
• Assess the potential impact of ASU No. 2024-03 (Disaggregation of Income Statement Expenses) for its effective date after December 15, 2026.

Key Dates

Recommendation

While Atossa Therapeutics shows promising early clinical data for (Z)-endoxifen in breast cancer and has secured valuable FDA designations for rare diseases, the company's severe financial distress, including substantial operating losses, declining cash reserves, and an explicit 'going concern' warning, presents an unacceptably high risk profile. The need for significant additional capital, coupled with ongoing patent challenges and a recent reverse stock split to maintain Nasdaq listing, indicates fundamental operational and financial instability. A seasoned investor would likely view the immediate financial risks as outweighing the long-term potential of its drug pipeline, suggesting a 'sell' recommendation until the company demonstrates a clear path to sustainable funding and profitability.

Keywords

(Z)-endoxifen, breast cancer, Duchenne Muscular Dystrophy, McCune-Albright Syndrome, SERM/D, clinical trials, Phase 2, biopharmaceutical, oncology, rare disease, FDA designation, Orphan Drug, Rare Pediatric Disease, Nasdaq, reverse stock split, patent litigation, capital raise, operating losses, biotechnology, mammographic breast density, DCIS